DSM-Firmenich AG

As of June 30, 2026, DSM-Firmenich AG carries a market capitalization of 20.01B, placing it among publicly traded companies globally. Its enterprise value stands at 24.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

DSM-Firmenich AG's next confirmed earnings release is scheduled for February 18, 2027.

As of June 30, 2026, DSM-Firmenich AG has 247.17M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, DSM-Firmenich AG maintains a current ratio of 1.75, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, DSM-Firmenich AG's stock has gained approximately 44.68% over the past 52 weeks. The 50-day moving average sits at 95.88, while the 200-day moving average is 76.59.

As of June 30, 2026, DSM-Firmenich AG holds 2.31B in cash and equivalents against 6.77B in total debt, resulting in a net debt position of 4.50B. Total book value stands at 17.83B, with working capital of 4.26B providing operational flexibility.